 |
|
Epidemiologic Review of the Calcium Channel Blocker Drugs
An Up-to-date Perspective on the Proposed Hazards
Jorge R. Kizer, MD, MSc;
Stephen E. Kimmel, MD, MSCE
Arch Intern Med. 2001;161:1145-1158.
In the setting of soaring popularity, postmarketing studies of calcium channel blockers came to suggest an increase in a variety of major adverse end points. The evidence, however, was largely observational, and large-scale trials capable of addressing the concerns were wanting. Clinical trials now support the safety and efficacy of the long-acting dihydropyridines for patients with both uncomplicated and diabetic hypertension, although conventional therapies and, in the latter case, angiotensin-converting enzyme inhibitors have superior proof of benefit. By contrast, short-acting dihydropyridines should be avoided. In the acute coronary syndromes,  -blockers remain the treatment of choice; the evidence for nondihydropyridines remains inconclusive. Stable angina calls for -blockers as first-line therapy and nondihydropyridines as second-line therapy, whereas in ventricular dysfunction, safety data for nondihydropyridines are lacking. Initial reports of cancer, bleeding, and suicide have been contradicted by subsequent data, making the associations uncertain or unlikely. Remaining questions await completion of ongoing trials to better define the indications for these agents.
From the Department of Medicine and Cardiovascular Division, University of Pennsylvania Medical Center (Dr Kizer) and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine (Dr Kimmel), Philadelphia.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED LETTER
Epidemiologic Evidence Existing for Calcium Antagonists
Giuseppe Zuccalà, Roberto Bernabei, Pierugo Carbonin, Alberto Cocchi, Jorge R. Kizer, and Stephen E. Kimmel
Arch Intern Med. 2001;161(21):2627-2628.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Translating Research into Practice: Are Physicians Following Evidence-Based Guidelines in the Treatment of Hypertension?
Holmes et al.
Med Care Res Rev 2004;61:453-473.
ABSTRACT
Calcium Restriction Allows cAMP Activation of the B-Raf/ERK Pathway, Switching Cells to a cAMP-dependent Growth-stimulated Phenotype
Yamaguchi et al.
J. Biol. Chem. 2004;279:40419-40430.
ABSTRACT
| FULL TEXT
Mortality Rates in Elderly Patients Who Take Different Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial Infarction: A Class Effect?
Pilote et al.
ANN INTERN MED 2004;141:102-112.
ABSTRACT
| FULL TEXT
Palliative Care for Patients With Heart Failure
Pantilat and Steimle
JAMA 2004;291:2476-2482.
ABSTRACT
| FULL TEXT
Calcium antagonists are associated with reduced mortality after cardiac surgery: a propensity analysis
Wijeysundera et al.
J. Thorac. Cardiovasc. Surg. 2004;127:755-762.
ABSTRACT
| FULL TEXT
Calcium antagonists reduce cardiovascular complications after cardiac surgery: A meta-analysis
Wijeysundera et al.
J Am Coll Cardiol 2003;41:1496-1505.
ABSTRACT
| FULL TEXT
Analysis of a Large Cohort of Health Maintenance Organization Patients With Congestive Heart Failure
Gladowski et al.
American Journal of Medical Quality 2003;18:73-81.
ABSTRACT
Bruce Psaty and the risks of calcium channel blockers
Deyo
Qual Saf Health Care 2002;11:294-296.
FULL TEXT
The Treatment of Hypertension in Adult Patients With Diabetes
Arauz-Pacheco et al.
Diabetes Care 2002;25:134-147.
FULL TEXT
Management of Hypertension in Patients with Type 2 Diabetes Mellitus: Guidelines Based on Current Evidence
Kaplan
ANN INTERN MED 2001;135:1079-1083.
ABSTRACT
| FULL TEXT
Epidemiologic Evidence Existing for Calcium Antagonists
Zuccala et al.
Arch Intern Med 2001;161:2627-2628.
FULL TEXT
|
